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1  | INTRODUC TION
T cells are adaptive immune cells that can become rapidly and ro‐
bustly activated when their T cell receptor (TCR) recognizes cognate 
foreign antigen. Upon this interaction, a signaling cascade from the 
TCR is triggered: these signaling events can be roughly divided into 
proximal kinases and more distal effector kinase pathways (Figure 
1). These components are coupled with the aid of several adapter 
molecules and second messengers. The process is further tuned by 
costimulatory molecules like CD28 and built‐in brakes like CTLA‐4 
and PD‐1. Ultimately, these signal transduction programs lead to full 
activation of the T cell and, depending on the cytokine milieu, dif‐
ferentiation of T cells into more specialized effector subsets such as 
Th1 and Th2.
Concomitant with T cell activation are changes in gene expres‐
sion and the synthesis of new proteins, one of which is the cytokine 
IL‐2, a critical cytokine that supports T cell survival. The coordinated 
activity of three transcription factors, nuclear factor of activated T 
cells (NFAT), nuclear factor kappa B (NFκB), and activator protein 1 
(AP‐1), is required for the production of IL‐2 (Figure 2). Additionally, 
activated, IL‐2 secreting T cells are remarkably proliferative, and as 
such they have a high metabolic demand. Over the past decade, it 
has become increasingly clear that metabolic reprogramming of the 
T cell is required to enable the transition from the naïve to the acti‐
vated state, and these metabolic changes are necessary to support 
T cell proliferation and effector functions. Furthermore, the meta‐
bolic demands of different helper T cell subsets are not identical. 
The kinase mechanistic/mammalian target of rapamycin (mTOR) 
plays an important role in the aforementioned processes of helper 
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Abstract
T cells play important roles in autoimmune diseases and cancer. Following the cloning 
of the T cell receptor (TCR), the race was on to map signaling proteins that contrib‐
uted to T cell activation downstream of the TCR as well as co‐stimulatory molecules 
such as CD28. We term this “canonical TCR signaling” here. More recently, it has 
been appreciated that T cells need to accommodate increased metabolic needs that 
stem from T cell activation in order to function properly. A central role herein has 
emerged for mechanistic/mammalian target of rapamycin (mTOR). In this review we 
briefly cover canonical TCR signaling to set the stage for discussion on mTOR signal‐
ing, mRNA translation, and metabolic adaptation in T cells. We also discuss the role of 
mTOR in follicular helper T cells, regulatory T cells, and other T cell subsets. Our lab 
recently uncovered that “tonic signals”, which pass through proximal TCR signaling 
components, are robustly and selectively transduced to mTOR to promote baseline 
translation of various mRNA targets. We discuss insights on (tonic) mTOR signaling 
in the context of T cell function in autoimmune diseases such as lupus as well as in 
cancer immunotherapy through CAR‐T cell or checkpoint blockade approaches.
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T cell activation, differentiation, and metabolic reprogramming. At 
the level of gene expression, the induction and activity of the tran‐
scription factor c‐Myc appears to be particularly important for T cell 
metabolic reprogramming.
The culmination of these signaling and transcriptional events is 
the extensive transformation from a naïve T cell to a proliferative, 
active cell that drives the immune response. Exactly how T cells re‐
spond to triggers from pathogen‐infected cells or transformed can‐
cer cells in an exquisitely sensitive manner, yet stay quiescent when 
encountering normal cells in the body (termed “self”) is still poorly 
understood. It is clear that to enact the above‐mentioned changes, T 
cells must exist in a “primed” state.
In this review, we aim to review the role of mTOR in transduc‐
ing and controling the signals involved in T cell activation, as well 
as cover the downstream functional consequences of mTOR activ‐
ity. In the first section of this review we will briefly discuss the well 
described, canonical TCR signaling cascade, including how the TCR 
engages proximal kinases, adapter molecules and second messen‐
gers to activate the key transcription factors required IL‐2 induction. 
We also refer the reader to additional literature in this first section 
for a more comprehensive overview of the field. From here we will 
we discuss the mTOR pathway in more detail and cover how mTOR 
signals and metabolic changes are essential to accompany the more 
traditionally studied pathways for T cell activation. We will describe 
what is known about how proximal TCR signaling events couple to 
mTOR and will discuss how mTOR integrates signals from the TCR 
as well as other upstream signal inputs such as nutrient availability 
to reshape T cell effector functions. We will describe work from our 
lab in which we show naïve T cells signal to mTOR in the basal state. 
RasGRP1, canonically an activator of the Ras pathway, mediates 
these tonic signals to mTOR. Tonic mTOR signaling impacts helper T 
cell differentiation and the translation of mRNAs into proteins. Our 
work points to a role for tonic mTOR signals in priming the transla‐
tional landscape in naïve T cells for the metabolic changes required 
upon activation. All this together suggests that mTOR serves to in‐
tegrate multiple signals in T cells, both in the basal state and upon 
TCR engagement by foreign cognate antigen. In the basal state, tonic 
mTOR signals “prime” T cells, and upon TCR stimulation these primed 
T cells engage mTOR to fully enable their activation, differentiation, 
and metabolic reprogramming. Lastly, we discuss how perturbations 
F I G U R E  1   Proximal TCR signaling, adapters, and second 
messengers. Simplified scheme of the canonical pMHC/TCR 
signaling pathway viewed as a linear relay system from TCR to 
transcription factors through proximal kinases, adapters, second 
messengers, and effector kinase pathways. pMHC, peptide‐major 
histocompatibility complexes; TCR, T cell receptor
F I G U R E  2   Requirements for induction of T cell activation. 
The second messenger molecules calcium and DAG trigger NFAT‐, 
AP‐1‐, and NFκB‐transcription factor pathways. At the same time, 
an activated T cell must induce metabolic changes to enable full 
and sustained activation and mTOR plays an important role herein. 
DAG, diacylglycerol; mTOR, mechanistic/mammalian target of 
rapamycin
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in tonic and inducible mTOR signaling in T cells can lead to disease, 
focusing on autoimmune disorders and cancer.
2  | PROXIMAL TCR SIGNALING , 
ADAPTERS,  AND SECOND MESSENGERS
In secondary lymphoid organs, T cells sample their surroundings via 
their TCR, making transient interactions with peptide‐major histo‐
compatibility complexes (pMHC) presented on the surface of anti‐
gen presenting cells. When pMHC‐TCR interactions are of sufficient 
affinity, a TCR signaling pathway is triggered through activation of 
proximal tyrosine kinases and the phosphorylation and assembly of 
adapter complexes, ultimately leading to changes in transcription 
and translation within the cell. The canonical “TCR signal” that we 
will briefly describe in the next four sections finds its way to the 
transcription factors NFAT, NFκB, and AP‐1, which together are re‐
quired to bind to the promoter of the key T cell survival cytokine IL‐2 
and induce its transcription1,2 (Figure 2). We will briefly describe this 
canonical TCR signaling pathway to provide the reader with context 
for our subsequent discussion of the mTOR pathway, tonic signaling, 
and the cellular functions they control.
Upon TCR ligation, a T cell undergoes vast changes mediated by a 
diverse array of distinct molecular events. Initiation of TCR signaling 
involves phosphorylation of the immunoreceptor tyrosine‐based ac‐
tivation motifs (ITAMs) of the TCR by the Src kinase Lck. Recruitment 
of Zeta‐associated protein of 70 kDa (Zap70) to the phosphorylated 
ITAMs sets up the top of the signaling cascade: Activated Zap70 is 
then able to phosphorylate a number of its effector substrates. For 
further reading on proximal kinase signaling in T cells we refer you 
to other literature3‐6 as well as to a review that describes how these 
proximal TCR signals may relate to kinetic proofreading.7
One critical substrate of Zap70 is the transmembrane adapter 
Linker for Activation of T cells (LAT). LAT has nine conserved ty‐
rosines that, when phosphorylated, provide docking sites for other 
proteins, leading to the assembly of a T cell signaling complex often 
called the “LAT signalosome.” The LAT signalosome is composed 
of LAT, the cytosolic adapter SH2‐domain containing leukocyte 
phosphoprotein of 76 kDa (SLP‐76), growth factor receptor‐bound 
protein 2 (Grb2), and other molecules. The exact identity of the LAT 
signalosome is unknown and it is not clear if there are different types 
of LAT signalosomes that are formed under different conditions that 
the T cell may encounter. Lck binds to LAT and essentially forms a 
bridge between Zap70 and its substrate, LAT.8 Excellent review ar‐
ticles have discussed the role of LAT and other adapter molecules in 
T cells.9‐11
One important downstream consequence of forming the LAT sig‐
nalosome is recruitment and activation of the enzyme PLCγ1 (phos‐
pholipase C gamma 1) at tyrosine 136 (murine LAT; Y132 for human 
LAT). PLCγ1 converts the membrane‐associated phospholipid PIP2 
(phosphatidylinositol 4,5‐bisphosphate) into two key second mes‐
senger molecules inositol trisphosphate (IP3) and diacylglycerol 
(DAG).12 T cell specific deletion of PLCγ1 leads to autoimmune and 
inflammatory diseases in mice. Looking specifically at the T cells, it 
was demonstrated that thymocyte development was impaired and T 
cells were unable to perform key functions such as proliferation and 
IL‐2 production.13
The two second messengers generated by PLCγ1, IP3, and DAG, 
are important for coupling the above‐described proximal TCR signal‐
ing molecules to the downstream transcription factors NFAT, NFκB, 
and AP‐1 to trigger T cell activation. Specifically, IP3 triggers calcium 
(Ca2+) release, which eventually leads to the activation of the tran‐
scription factor NFAT. DAG recruits and activates several signaling 
proteins that play a role in T cell biology: these include the protein 
kinase C family (PKCs) and the Ras guanine nucleotide releasing pro‐
tein (RasGRP) family members. We will summarize IP3 and DAG sig‐
naling in T cells in the next sections.
3  | C ALCIUM SIGNAL S AND NFAT 
AC TIVATION
When T cells are activated by pMHC/TCR signals, calcium concen‐
trations rapidly increase 10‐fold from 100 nmol/L to 1 μmol/L, a 
phenomenon termed a “calcium flux.” Calcium flux leads to activa‐
tion of NFAT as well as other molecules.14‐16 One manner by which 
calcium can activate effector proteins is by binding to a type of pro‐
tein domain called an EF hand. EF hand domains are characterized 
by a helix‐loop‐helix structure and often come in pairs in signaling 
molecules. Binding of a calcium ion to the EF domain results in a 
repositioning of the directional vectors of the two helices and often 
to a conformational change of the entire signaling molecule with the 
EF hands.17 For more reading on how calcium connects to NFAT via 
EF hand‐containing proteins, please see.14,15,18
4  | DIACYLGLYCEROL CONNEC TS TO 
NFκB AND AP‐1 PATHWAYS
NFAT alone is insufficient to fully activate T cells. To fully induce 
T cell activation and production of IL‐2, NFAT must synergize with 
NFκB and AP‐1 (Figure 2). This is where DAG, a hydrophobic com‐
ponent of cellular membranes, comes in.19,20 DAG is a potent sign‐
aling molecule as well as a metabolic source of fatty acids, as it is 
composed of fatty acids and glycerol molecules.19 Illustrative for the 
importance of DAG as second messenger, there are different man‐
ners to metabolize DAG. For example, diacylglycerol kinases (DGKs) 
can phosphorylate DAG thereby converting it to phosphatidic acid. 
When two of these enzymes, DGKα and DGKζ, are simultaneously 
deleted in mice, normal T cell development is perturbed as a result 
of elevated DAG‐driven signaling.21 For more reading on DAG meas‐
urements and localization we suggest these studies.12,22,23 DAG can 
induce membrane recruitment of proteins through a conserved 50 
amino acid sequence termed “C1 domain”; a hydrophobic cup‐like 
structure that binds DAG.24 Various signaling proteins contain C1 
domains, PKCs,25 RasGRPs,26 protein kinase D (PKD),27 chimaerin 
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family proteins, and munc13 proteins.20 We will focus on the PKCs, 
which couple to NFkB, and RasGRP1, which couples to AP‐1 via Ras, 
in this review.
5  | DAG ‐INDUCED NFκB AC TIVATION IN T 
CELL S
The PKC family of serine/threonine kinases couple DAG production 
to the activation of NFκB. In T cells, PKCθ is the PKC family member 
that appears to be dominant in T cells, and it is recruited to the plasma 
membrane upon TCR ligation and DAG generation.28‐31 Binding of 
PKCθ to DAG at the membrane relieves autoinhibition of the mol‐
ecule, putting it into an “open/active” conformation that is able to 
bind and phosphorylate its substrates.32 Experiments utilizing small 
molecule inhibitors of PKCθ or antisense oligos revealed their critical 
role in the activation of the transcription factors NFκB and AP‐1.33,34 
Two independent groups generated PKCθ knockout mice and further 
corroborated PKCθ's connection to AP‐1 and NFκB pathways in T 
cells.29,35 PKCθ was also shown to phosphorylate RasGRP1; this pro‐
vided a mechanistic link for how PKCθ connects to AP‐1, as AP‐1 is 
directly downstream of the RasGRP1‐Ras‐MAPK pathway.36
6  | THE R A S E XCHANGE FAC TOR 
R A SGRP1 COUPLES TCR STIMULUS TO AP‐1 
AC TIVATION
RasGRP1 is a guanine nucleotide exchange factor (GEF) for the small 
GTPase Ras. Ras cycles between a GTP‐bound “on” state where it 
signals to activate the mitogen‐activated protein kinase (MAPK) 
pathway, and a GDP‐bound “off state” where it is not signaling. 
Activated Ras is a strong driver of cell proliferation and activating 
mutations are amongst the most frequent mutations in metastatic 
cancers.37 Non‐cancerous cells also GTP‐load Ras, and interest‐
ingly, T cells were the first non‐transformed cell type in which this 
was demonstrated.38 The canonical Ras‐ERK pathway consists of 
Ras‐GTP binding the kinase RAF, which phosphorylates of MEK 
(mitogen‐activated protein kinase kinase), culminating in phospho‐
rylation of ERK1/2 (extracellular signal regulated kinase 1/2).39 
Phosphorylation of ERK1/2 activates ERK to act on a number of cy‐
tosolic proteins and transcription factors via its kinase activity. ERK 
signaling leads to the induction of Jun and Fos expression and a het‐
erodimer of the Jun/Fos transcription factors composes AP‐1.2 The 
importance of ERK is further exemplified by the impaired positive 
selection of thymocytes when Erk1 and Erk2 are deleted.40 RasGTP 
has also been shown to recruit the lipid kinase phosphoinositide 3‐
kinase,41‐43 resulting in activation of PI3K, production of PIP3 and 
signal transduction to Akt, which in turn has many targets including 
mTOR.43
Exchange factors for Ras displace GDP from Ras‐GDP and re‐
lease empty (non‐nucleotide bound) Ras that subsequently binds 
either GDP or GTP. Given that intracellular GTP concentrations are 
higher than GDP, this leads to accumulation of RasGTP in a stochas‐
tic manner. T cells utilize two families of RasGEFs: son of sevenless 
(SOS) and RasGRP1. For a comprehensive review on SOS in T cells, 
see Jun et al.44 For further reading on the RasGRP family of GEFs, 
which includes RasGRP1, see Ksionda et al.26
In RasGRP1, the catalytic module of the REM (Ras exchange 
motif) and a CDC25 domain is followed by a pair of EF‐hands, a C1 
domain, and a coiled‐coil domain. Our lab collaborating with the 
Kuriyan lab solved the initial crystal structure of RasGRP1. This 
structure revealed that RasGRP1 exists as an autoinhibited dimer 
in the basal state and provided key insights into how RasGRP1 ac‐
tivity is regulated. We found that the C1 and EF hands negatively 
regulate the intrinsic activity of the catalytic domain of RasGRP1.45 
The crystal structure demonstrated that a dimer interface between 
these domains prevents DAG binding by capping off the C1 domain. 
Specifically, the C1 domain of one RasGRP1 monomer contacts 
the EF2 and CDC25 domains of the other, which likely prevents 
RasGRP from binding to DAG. Additionally, a linker domain be‐
tween the CDC25 and EF hands runs through the cleft of the cata‐
lytic pocket in a configuration that is incompatible with Ras binding 
to the catalytic pocket.45 Co‐crystals of exchange factor family 
member RasGRP2 with Rap1b and RasGRP4 with H‐Ras provided 
insights as to how calcium and DAG result in activation of RasGRP1, 
and a pH‐sensor histidine residue conserved in all RasGRPs plays 
a prominent role in the rearrangement from the inactive to active 
conformation of a RasGRP molecule.46 Lastly, the RasGRP1 protein 
contains a C‐terminal coiled‐coil which allows for RasGRP1 homod‐
imerization45 (and unpublished data from the Roose lab). A mouse 
model where endogenous Rasgrp1 was genetically modified with a 
version that lacked the tail domain revealed that the C‐terminal tail 
has an important functional role in vivo. These Rasgrp1 tail‐defi‐
cient mice exhibit autoimmune features, and have impaired thymo‐
cyte development and T cell proliferation.45
Fully Rasgrp1‐deficient mice revealed an important role for this 
Ras GEF in T cell development. Thymocytes in Rasgrp1 knockout 
mice are blocked at the double‐positive (DP) stage, and as such 
very few mature T cells populate the peripheral lymphoid organs.47 
Rasgrp1‐deficient thymocytes exhibit impaired TCR‐induced Erk 
phosphorylation in vitro, which likely explains the in vivo block at 
the DP stage, as DP thymocytes require a productive Ras‐Erk signal 
for positive selection.40
7  | R A SGRP1 AND DISE A SE
Data from human patients as well as genetic mouse and cell line 
models have demonstrated that RasGRP1 activity must be properly 
controlled to prevent disease. For example, RasGRP1's normal rest‐
ing auto‐inhibitory state can be overwhelmed by overexpression 
such that T cell leukemia develops.48‐50 We found that overexpres‐
sion of RasGRP1 drives T cell acute lymphoblastic leukemia (T‐ALL), 
and that this mechanism of oncogenesis is distinct from mutant Ras, 
as the two genetic aberrations are mutually exclusive.48,51
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RasGRP1 has also been implicated in immunodeficiencies and 
autoimmune diseases. Loss of RasGRP1 in patients leads to immu‐
nodeficiency, impaired cytotoxic T cell and NK T cell functions, 
and susceptibility to bacterial and viral infections.52‐55 Mice with 
point mutations in Rasgrp1 have also been created in addition to 
genetic deletions or forced overexpression. One such variant is 
the Rasgrp1Anaef mouse. These mice harbor a missense point mu‐
tation (R519G) in the EF2 domain such that basal autoinhibition is 
weakened.56 As we will discuss extensively throughout this review, 
these mice exhibit increased basal mTOR signaling that leads to a 
lupus‐like phenotype.56 Interestingly, splice variants in RasGRP1 
have been identified in human systemic lupus erythematosus pa‐
tients. Additionally, variants in RasGRP1 have been associated with 
type 1 diabetes and Graves' disease, and loss of precise regulation 
of RasGRP1 expression levels appear to underlie the autoimmune 
disease in some of these patients.57‐60
T cells harboring the Rasgrp1Anaef variant exhibit increased base‐
line mTOR signaling, yet the expression of Ras target genes such as 
the activation marker CD69 remains unchanged.56 This suggests that 
Rasgrp1 may serve dual roles upon TCR stimulation to not just acti‐
vate the classical Ras‐Erk pathway, but secondarily engage the mTOR 
pathway.
8  | MTOR SIGNALING
Now that we have set the stage by describing canonical TCR sign‐
aling with several pathways converging on induction of IL‐2, and 
discussed RasGRP1‐Ras‐ERK signaling, we will next focus on the 
mTOR pathway. mTOR is classically known to be a critical regula‐
tor of cell growth, proliferation, and mRNA translation. The bio‐
chemical details of this pathway have been largely characterized 
in cell lines, and the physiological role of mTOR signaling has been 
widely studied in a number of model organisms and disease states 
such as cancer. In T cells, it is known that mTOR becomes acti‐
vated upon TCR ligation, however, the molecular details that con‐
nect the TCR to mTOR are still being elucidated. Work from our lab 
and others have implicated a role for Rasgrp1 in mTOR activation, 
as Rasgrp1‐deficient mouse thymocytes exhibit impaired TCR‐in‐
duced S6 phosphorylation.61 In the next sections, we will provide 
an overview of the mTOR signaling pathway and the downstream 
cellular functions it controls, with a particular focus on T cell biol‐
ogy. Additionally, we have found that there is robust basal (tonic) 
activity through the mTORC1 pathway in naive T cells, and we 
identified a role for Rasgrp1 in this tonic mTORC1 signaling.56,62 
We will discuss this work on tonic mTORC1 in T cells and discuss 
how tonic signals may be altered in disease contexts such as auto‐
immunity and cancer.
9  | MTOR SIGNAL S THROUGH T WO 
DISTINC T COMPLE XES:  MTORC1 AND 
MTORC2
mTOR is a serine/threonine kinase that associates with several co‐
factors to form two distinct complexes, mTORC1 and mTORC2. The 
accessory protein regulatory‐associated protein of mTOR (RAPTOR) 
is a critical component of complex 1, whereas rapamycin‐insensitive 
companion of mTOR (RICTOR) has an analogous role in mTORC2. 
RAPTOR and RICTOR function as scaffolds to bring the complexes 
together and for binding substrates63 (Figure 3). mTORC1 can be ac‐
tivated by diverse signal inputs such as nutrients and growth factors 
from the microenvironment (reviewed in 64‐66), and these receptor 
inputs have also been shown to couple to the lipid kinase PI3K. PI3K 
F I G U R E  3   mTOR kinase complexes 
mTORC1 and mTORC2. The kinase mTOR 
can partner with different signaling 
molecules to form either an mTORC1‐ or 
mTORC2‐complex that have distinct 
substrates. In the mTORC1 complex, 
Raptor can bring mTOR to RagA/B 
and RagB/C, localizing mTORC1 to the 
lysosome. mTOR, mechanistic/mammalian 
target of rapamycin
     |  139MYERS Et al
produces phosphatidylinositol (3,4,5)‐triphosphate (PIP3), which ac‐
tivates phosphoinositide‐dependent protein kinase‐1 (PDK1). PDK1 
subsequently activates Akt at the plasma membrane. Akt phospho‐
rylates and inhibits the Ras homolog enriched in brain (Rheb) GTPase 
activating protein (GAP) complex tuberous sclerosis complex 1/2 
(TSC1/2). The net result is activation of the small GTPase Rheb (GTP‐
bound Rheb), which in turn activates mTORC1. In T cells, exactly 
how TCR signals couple to mTOR activation is not fully understood.
Following activation, mTORC1 directly phosphorylates its 
substrates: the S6 kinases (S6K1 and S6K2) (which phosphory‐
late the ribosomal S6 protein, referred to as S6 throughout this 
review) and the eukaryotic translation initiation factor 4E (eIF4E) 
binding proteins (4E‐BP1, 2, and 3) (Figure 4). It is still relatively 
unclear what upstream cues activate mTORC2, but it is firmly es‐
tablished that mTORC2 activity results in the phosphorylation and 
activation of AGC‐family kinases such as Akt and SGK1.64,65,67,68 
Interestingly, it seems that T cells may have a distinct pathway for 
turning on mTORC1, as mTORC1 activation in CD8+ T cells occurs 
independently of PI3K or Akt. Treatment with the Akt inhibitor 
Akti‐1/2 or with the p110δ inhibitor IC87114 does not impact 
phosphorylation of downstream mTORC1 effectors S6K, S6, and 
4E‐BP1.69
10  | METABOLITES THAT ENABLE MTOR 
SIGNALING
mTOR activation is contingent upon its localization to the lysosome, 
a process which is regulated by amino acids and the Rag GTPases. In 
response to amino acid import, the Rag GTPases exist as heterodimers 
between either RagA or RagB and either RagC or RagD. In response to 
amino acid stimulation, RagA/B becomes GTP loaded and RagC/D be‐
comes GDP‐loaded, which are the active conformations. Rag GTPases 
then induce the localization of mTOR to the lysosome, via binding to 
RAPTOR (Figure 3). mTOR is also able to localize with the GTPase 
Rheb at the lysosome surface, facilitating its activation independent of 
the Rag complexes.63,70,71 These foundational studies were performed 
in HEK‐293T cells; more recently, it was shown that Rag GTPases also 
facilitate localization of mTORC1 to the lysosome in T cells.65,72
Upstream activation of mTOR signaling is balanced by the AMP‐
activated protein kinase (AMPK) pathway. AMPK senses when ATP 
levels in cells drop (and the AMP/ATP ratio rises) and AMPK phos‐
phorylates TSC2. Phospho‐TSC2 has increased GAP activity towards 
Rheb‐GTP, effectively shutting off mTOR signaling.73 Overall, AMPK 
signals promote catabolic processes instead of the anabolic ones uti‐
lized in highly metabolic, glycolytic cells.74 A striking cell biological 
effect of active mTOR signaling is the alteration in cell metabolism; 
switches in metabolic programs are concomitant with an increase 
in cell growth, cap‐dependent translation and elongation, and ribo‐
some biogenesis.64 Thus, receptor signals, metabolites, and energy 
state regulate mTOR signaling, and mTOR in turn enables metabolic 
changes in the cell.
11  | MTOR REGUL ATES MRNA 
TR ANSL ATION
When cells are in nutrient‐rich environments that support growth and 
proliferation, cells need to increase their cell size. To meet the biosyn‐
thetic demands of this growth, cells need to be able to produce new 
proteins through a process known as translation (Figure 4). Translation 
is energetically costly to the cell (each amino acid costs the cell 5 ATP 
on average75), and as such it is very tightly regulated and only occurs 
under favorable conditions. mTOR and AMPK, as described previ‐
ously, are key sensors of these environmental cues, and provide the 
cell with a mechanism with which to couple nutrient availability to 
energetically demanding cellular processes such as translation.
Translation is typically divided into four phases: initiation (the 
rate‐limiting step wherein an elongation‐competent 80S ribosome is 
assembled and pairs with an mRNA), elongation (where new amino 
acids are joined to the nascent polypeptide), termination, and re‐
cycling.76,77 Mechanistically, mTOR regulates translation initiation 
through its action on the 4E‐BPs and the S6 kinases. Active S6K1 
stimulates the production of ribosomes by phosphorylating and in‐
teracting with several effector proteins that promote translation of 
mRNAs with 5′ terminal oligopyrimidine (5′TOP) features, including 
elongation factors and cap‐binding proteins.63 Ribosomes do not 
F I G U R E  4   mTORC1 regulates mRNA translation on ribosomes 
and mTOR‐responsive mRNA elements. mTORC1 signaling to 
S6K and to 4E‐BP1 or 4E‐BP2 to liberate eIF4E can result in 
increased biogenesis of ribosomes and translation of target mRNAs. 
mTOR, mechanistic/mammalian target of rapamycin
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directly bind to mRNAs, but are recruited to mRNAs by eukary‐
otic translation initiating factors, or eIFs. One of these eIFs, eIF4E, 
binds to the 5′ cap present on all transcribed mRNAs. However, in 
non‐activated cells, eIF4E is not bound to the 5′ cap but complexes 
with hypo‐phosphorylated 4E‐BPs. When cellular conditions are 
favorable and mTORC1 signaling is activated, mTORC1 phosphory‐
lates 4E‐BP, leading to dissociation of 4E‐BP from eIF4E (Figure 4). 
eIF4E is subsequently free to bind to the 5′ cap of mRNAs. At this 
point, it also associates with two other proteins: eIF4G (a scaffold) 
and eIF4A (an RNA helicase that unwinds complex 5′ untranslated 
regions [5′UTR] structures in the mRNAs). eIF4G also interacts with 
eIF3, an important ribosome‐initiation factor, and the “ternary com‐
plex” (eIF2, Met‐tRNA, and GTP) are also recruited to the mRNA.73,78 
Once these effectors are in place, the ribosome can then scan the 
mRNA in a 5′ to 3′ direction, generating a new polypeptide.
12  | MTOR‐RESPONSIVE MRNA 
ELEMENTS
mTORC1‐S6K signaling has also been shown to play a role in both 
translation initiation as well as ribosome biogenesis, which is essen‐
tial for efficient translation. mTORC1 phosphorylates S6K1 at threo‐
nine 389, which results in the formation of a docking site for the 
kinase PDK1, which phosphorylates S6K1 at T229, fully activating 
S6K. S6K can phosphorylate another initiation factor, eIF4B, and in 
turn eIF4B enhances the helicase activity of eIF4A.73 This process is 
particularly important for the translation of mRNAs that have long 
and highly structured UTRs. A notorious example is c‐Myc, which 
will be discussed a later point in this review. The particular nature 
of the 5′UTR structures of potential mTOR targets is an area of ac‐
tive investigation. Some groups previously documented that mTOR 
targets have long 5′UTRs, whereas a study from the Ruggero lab re‐
vealed mTOR‐dependent mRNAs have short 5′UTRs.79 Interestingly, 
in prostate cancer cell lines, 68% of mTOR‐responsive mRNAs have 
these above‐mentioned 5′TOP features, 63% possess a newly iden‐
tified pyrimidine‐rich translational element (PRTE), and 89% encom‐
pass either a 5′TOP or a PRTE79 (Figure 4). Whether these elements 
are indicative of mTOR‐responsiveness in cell types other than pan‐
creatic cell lines, such as T lymphocytes, is still unknown.
13  | TARGET mRNA S OF MTOR IN T CELL S
It appears that T cells with different activation states, that is naive 
vs ex vivo TCR‐stimulated, and with different effector functions, 
such as conventional vs regulatory CD4+ T cells, have different 
translational programs. Bjur and colleagues compared the transla‐
tional landscapes of aforementioned populations by isolating poly‐
some‐associated mRNAs from ribosomes80 and documented that 
the translational programs in these cell populations were distinct 
from each other and the characterized transcriptional profiles. Thus, 
mRNA translation is distinct in different T cell populations.
The transcription factor c‐Myc has been shown to be regulated 
at the level of mRNA translation. Biochemically, c‐Myc is induced 
downstream of PI3K, mTOR, and ERK signaling, as its induction 
can be blocked with inhibitors of these kinases.81 Raptor‐deficient 
CD4+ T cells also do not upregulate c‐Myc protein.82 Myc is induced 
early in T cell activation, prior to upregulation of metabolic genes, 
suggesting that Myc itself could play a role in inducing metabolic 
reprogramming.81 Interestingly, c‐Myc expression is regulated in a 
sensitive manner: first, it appears that Myc mRNA and protein are 
induced in a digital fashion, meaning that Myc is either expressed 
or not expressed at all in the cell, downstream of TCR signaling. Yet 
c‐Myc protein levels are regulated at the post‐transcriptional level 
in a more graded, analog fashion downstream of IL‐2R signaling. 
This was revealed by stimulating OT‐1 T cells with agonist peptides 
of varying affinities and by culturing cells in different amounts of 
IL‐2. These data suggest that TCR‐activating signals generate some 
c‐Myc expression in cells, but its exact levels are fine‐tuned based 
on environmental cues such as the presence of cytokines.
Several genes important for Th2 and Tfh biology have been 
shown to be regulated at the translational level, including Gata3 
and IL‐4.76 Gata3 is the master transcription factor for Th2 cells, 
which produce IL‐4. Naïve T cells differentiate into Th2 cells in 
the presence of TCR stimulation and IL‐4 cytokine input. Gata3 
gets induced and then binds to the IL‐4, ‐5, and ‐13 locus, inducing 
the transcription of these cytokines.83,84 Cook and Miller showed 
that signaling through the IL‐4 Receptor in T cells can increase 
Gata3 mRNA levels somewhat, but not to a degree that is suffi‐
cient for Th2 differentiation. Only with TCR stimulation, activat‐
ing the mTOR pathway, do Gata3 protein levels rise sufficiently. 
Furthermore, TCR stimulation together with IL‐4 increases Gata3 
translation in T cells, as Gata3 protein levels increase in a radio‐la‐
beled methionine assay, while mRNA levels stay constant.85 IL‐4 is 
under translational control in Th2 cells that are re‐activated after 
initial priming, leading to increased polysomes and increased IL‐4 
protein production.86 Interestingly, the ICOS costimulatory mole‐
cule is important for this translational control. ICOS costimulation 
augments IL‐4 mRNA translation, as IL‐4 mRNA was enriched in 
polysome fractions following TCR + ICOS stimulation compared to 
stimulation with TCR alone.87 This was dependent on ICOS‐PI3K 
signaling, as no increase in polysome association was observed in 
mice with an ICOSY181F mutation that abrogates the ability of ICOS 
to activate PI3K. The ICOS‐PI3K loop was suggested to be import‐
ant for targeted delivery of IL‐4 cytokine to B cells by Tfh cells 
during the germinal center response. In sum, the role of mRNA 
translation regulating T cell function requires further studies, but 
results thus far point to an interesting link with Th2 differentiation.
14  | MTOR‐DEPENDENT GROW TH AND 
PROLIFER ATION IN ANIMAL MODEL S
mTOR has been well‐established as a regulator of cell mass and 
proliferation. Drosophila with crippling mutations in PI3K, Akt, and 
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mTOR have reduced cell, organ, and organism size, and, conversely, 
mutations in PTEN, an important negative regulator of PI3K signal‐
ing, lead to increased cell growth (summarized in 88). mTOR is impor‐
tant in embryonic development, as mTOR‐deficient Drosophila die in 
the pupal stage,88 and a whole‐body knockout of mTOR in mice is 
embryonic lethal.89 Mice with reduced mTOR levels, caused by a neo 
cassette insertion that partially disrupts mTOR transcription, have 
reduced overall size and weight. We found that mTORchino mice with 
I205S substitution in the Raptor‐binding domain of mTOR resulting 
in a hypomorphic mTOR allele show reduced body mass as well.56 
Global deletion of S6K1, a downstream effector of mTOR, also ef‐
fects growth and proliferation, as S6K1‐deficient mice have reduced 
overall mass and a developmental delay.90
15  | MTOR‐REL ATED GROW TH DEFEC TS 
IN LYMPHOCY TES
With respect to the immune system, the mice with a neo insertion 
in mTOR have reduced spleen size and reduced numbers of T and B 
cells. T cells exhibited impaired proliferation in response to stimula‐
tion with α‐CD3 and CD28 antibodies, which activate the TCR and 
provide costimulation, respectively.91 Another group generated 
a T cell specific mTOR knockout mouse by crossing mTORfl/fl ani‐
mals to CD4‐Cre, and T cells from these animals showed impaired 
TCR‐induced proliferation as well.92 Impairing mTOR kinase activ‐
ity in mouse B or T cells with a kinase‐dead knock‐in allele crossed 
to CD19‐Cre or CD4‐Cre profoundly reduced cell size and impaired 
proliferation, as did T cell specific knockout of Raptor, one of the 
critical components of mTORC1.93 Interestingly, T and B cells from 
S6K1/2 double‐deficient mice grew and proliferated normally, indi‐
cating that the S6Ks are not essential for these processes. Instead, 
this study proposed that the 4E‐BPs predominantly regulate growth 
and proliferation in lymphocytes. This study also revealed that 
4E‐BP2 is the dominant isoform expressed in lymphocytes, as op‐
posed to 4E‐BP1 which is more abundant in other cell types such as 
fibroblasts.93
16  | HELPER T CELL DIFFERENTIATION IS 
CONTROLLED BY MTORC1 AND MTORC2
In T cells, there has been a great deal of recent interest in mTOR sign‐
aling and its role in peripheral T cell biology, including helper T cell 
differentiation92,94‐96 (Figure 5) and lymphocyte metabolism,74,97,98 
which we will discuss in the subsequent sections. Although we will 
not cover it in this review, important work has also revealed a role for 
mTOR in B:T cell interactions in the germinal center and the expres‐
sion of adhesion molecules that mediate lymphocyte trafficking. For a 
discussion of this topic we point the reader to this excellent review.99
When a naïve CD4+ T cell receives TCR input in the appropriate 
cytokine milieu, the cell becomes activated and can begin a program 
of proliferation and differentiation into effector subsets.100 Th1 
cells produce IFNγ, express the transcription factor T‐bet, and are 
important for immunity to intracellular pathogens; Th2 cells (men‐
tioned above for being regulated in part by mRNA translation) ex‐
press Gata3, produce IL‐4 and IL‐13, and are important for immunity 
to helminths (yet are pathogenic in atopic diseases). Th17 cells are 
pro‐inflammatory and produce IL‐17. Follicular helper T cells (Tfh) 
express the transcription factor Bcl6 and are important for provid‐
ing help to B cells in the germinal center response. For example, Tfh‐
derived IL‐4 can promote class switching to IgG1 and IgE in mice.101 
Regulatory T cells, which suppress effector T cell responses, can 
develop in the thymus (called natural Treg, or nTreg) as well as in‐
duced in the periphery (induced Treg, or iTreg) as a means to ensure 
tolerance.
It has been appreciated that mTOR signaling plays an important 
role in the above‐described helper T cell activation and fate deter‐
mination. TCR‐stimulated mTOR‐deficient T cells do not upregulate 
activation markers or proliferate well. Additionally, mTOR deficient 
T cells preferentially become regulatory, and not effector T cells.92 
Abrogating either mTORC1 signaling (via T cell specific Rheb KO) or 
mTORC2 signaling (via T cell specific Rictor KO) in CD4+ T cells re‐
vealed that mTORC1 is essential for Th1 and Th17 differentiation, 
whereas Th2 cells require mTORC2.94 A separate study revealed a 
F I G U R E  5   mTORC1 and mTORC2 signals and helper T cell 
differentiation. Signals through the mTORC1 or mTORC2 kinase 
complexes impact the efficiency of CD4 T cells to differentiate into 
distinct effector T cell populations. Studies with mouse models 
and deletion of Raptor or Rictor were instrumental to propose 
the concept depicted in Figure 5. mTOR, mechanistic/mammalian 
target of rapamycin
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role for mTORC1 in Th2 differentiation, using T cell specific Raptor 
knockout to eliminate mTORC1 signaling.82 T cell specific deletion 
of the AGC kinase family member SGK1, which, just like its family 
member Akt, is downstream of mTORC2, led to a modest reduction 
in T cell proliferation but a profound defect in the generation of Th2 
cells as measured by IL‐4, ‐5, and ‐13 production.67 Subsequently, 
two groups independently identified a role for both mTORC1 and 
mTORC2 signaling in the generation of Tfh cells (PD1high CXCR5+) 
and the germinal center reaction, finding that Raptor‐, Rictor‐ and 
mTOR‐deficient T cells could not differentiate to Tfh, had reduced 
numbers of GC B cells and reduced production of antibodies by 
those B cells95,96 (Figure 5).
mTOR is also active in regulatory T cells (Tregs) and plays a criti‐
cal role in their function. Freshly isolated CD25high regulatory T cells 
exhibit higher mTOR activity, read out by P‐S6K and P‐S6, relative 
to CD25low effector T cells.83,102 To determine the functional role 
of mTORC1 signals in Tregs, mice with a Treg specific deletion of 
mTORC1 signaling (FoxP3‐Cre Raptorfl/fl) were generated.83 Strikingly, 
these mice exhibited severe inflammation associated with immune 
cell infiltration in multiple tissue types. Effector T cells in these 
mice had an effector/memory phenotype (CD44high CD62Llow) and 
produced cytokines such as IFNγ, which suggests that the Tregs in 
these mice were unable to effectively suppress conventional T cells. 
To confirm that Raptor‐deficient Tregs have impaired suppressive ca‐
pacity, the authors utilized the adoptive T cell transfer colitis model. 
In this model, adoptive transfer of effector T cells into Rag1−/− hosts 
leads to development of colitis in mice, and this can be prevented 
by co‐transferring WT Tregs. The authors found that co‐transfer of 
Raptor‐deficient Tregs did not prevent colitis, consistent with im‐
paired suppressive capacity of Raptor‐deficient Treg in vivo.83 In sum, 
it has become evident that mTOR signaling is closely tied to CD4+ T 
cell fate decisions, and in the next sections we discuss how this may 
occur through the effects of mTOR signaling on metabolism.
17  | METABOLIC PROGR AMS IN NAIVE , 
AC TIVATED, AND REGUL ATORY T CELL 
SUBSETS
There has been a flood of research into the role of metabolic pro‐
grams used by CD4+ T cells (and other immune cells, which we will 
not cover here), and the role of mTOR therein. By now it is well es‐
tablished that T cells in different activation states dynamically adopt 
different metabolic programs to meet their functional needs. Naïve, 
quiescent T cells that are not actively dividing or producing cytokines 
generate most of their energy by converting glucose to pyruvate and 
oxidizing that pyruvate in the mitochondria (TCA cycle), a process re‐
ferred to as oxidative phosphorylation or OXPHOS. Once T cells be‐
come activated and differentiate into effector cells, their metabolic 
demand greatly increases, and, as such, they respond by primarily 
utilizing a different metabolic pathway: aerobic glycolysis. Glycolysis 
is not an energy‐efficient process as it only yields two molecules of 
ATP per input molecule of glucose, but it is advantageous to rapidly 
dividing cells because it generates many biosynthetic precursors for 
cell growth.103
Several of the different effector T cell subsets (Th1, Th2, and 
Th17) have been shown to utilize aerobic glycolysis.104 Additionally, 
cells can obtain energy through the oxidation of lipids instead of glu‐
cose. Tregs primarily gain energy via lipid oxidation and have higher 
levels of AMPK, though it has been shown that Tregs do utilize 
glycolysis when proliferating. Interestingly, it seems that there are 
tradeoffs between metabolism and function, as these proliferating 
Tregs that use a more glycolytic metabolic program have reduced 
suppressive capabilities.105 Cholesterol biosynthesis also appears to 
be regulated by mTORC1 signaling in Tregs, as Raptor‐deficient Tregs 
had reduced expression levels of cholesterol biosynthesis pathway 
genes, and these cells failed to perform de novo lipid synthesis or 
maintain levels of intracellular cholesterol upon TCR stimulation.83 
At the end of an immune response, memory cells form, and these 
typically utilize lipid oxidation.97 Inhibiting mTOR with rapamycin, 
or activating AMPK with metformin, can promote the generation of 
memory CD8+ T cells, suggesting a further link between T cell me‐
tabolism and function.106,107
In addition to TCR signaling, costimulatory signals can also 
control these metabolic changes. Cells primed with CD28 in vitro 
exhibited enhanced glycolysis and also had increased spare re‐
spiratory capacity compared to T cells that did not receive CD28 
costimulation, indicative of a role for CD28 signaling in mitochon‐
drial metabolism. This appears to be particularly important for 
the generation of functional cytokine‐secreting memory T cells. 
Mechanistically, CD28 signaling promotes expression of carnitine 
palmitotransferase 1a (Cpt1a), which facilitates fatty acid oxida‐
tion. This CD28‐Cpta1 axis was important for memory T cell func‐
tion in vivo in a tumor model: T cells primed with TCR and CD28 
stimulation were able to control the growth of EL4 tumors long‐
term, whereas T cells primed in the same fashion yet also treated 
with the Cpt1a inhibitor etomoxir (ETO) could initially control tu‐
mors (indicative of an intact effector T cell response), but after 
several weeks tumors grew out, consistent with an impaired mem‐
ory T cell response.108
18  | REPROGR AMMING FROM OXPHOS 
TO AEROBIC GLYCOLYSIS
The reprogramming from OXPHOS to aerobic glycolysis involves 
several cell‐biological changes. First, activated cells upregulate 
transporters to bring in glucose, amino acids, and other nutrients. 
These include glucose receptor Glut1,109 the trophic receptor CD71 
(transferrin receptor), and CD98 and SLC7A5, which together form 
a heterodimeric large neutral amino acid transporter, LAT1.110,111 
Additionally, activated T cells upregulate certain transcription fac‐
tors, such as ERRα and c‐Myc, which in turn enhance expression of 
metabolic genes.74,97
The glucose transporter Glut1 is expressed at low levels in rest‐
ing T cells, but Glut1 protein expression dramatically increases and 
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is accompanied by increased trafficking to the plasma membrane 
when T cells are activated in vitro.109 Surface Glut1 is also induced 
on T cells in vivo in response to immunization.104 Treatment of in 
vitro activated T cells with PI3K and mTOR inhibitors demonstrated 
that these kinases are required for Glut1 induction. Interestingly, it 
seems that Glut1 is important for sustaining mTORC1 signaling once 
T cells are already activated, as cultured Glut1‐deficient T cells ex‐
hibit reduced P‐S6 levels and increased P‐AMPK levels (indicating 
metabolic stress) compared to WT, suggesting a positive feedback 
loop.109
Mouse models of Glut1 overexpression104 or deficiency109 re‐
vealed an important functional role for Glut1 in T cell proliferation, 
survival, and cytokine production. Measuring OXPHOS levels via the 
oxygen consumption rate and aerobic glycolysis via the extracellular 
acidification rate revealed that Glut1‐deficient cells could not un‐
dergo metabolic reprogramming from OXPHOS to glycolysis. These 
studies reveal a critical role for cellular import of glucose in lympho‐
cyte activation, proliferation, and metabolism.
The process of aerobic glycolysis itself is important for T cell ef‐
fector function, as naïve CD4+ T cells stimulated in media contain‐
ing galactose (which cannot be metabolized using aerobic glycolysis) 
were dramatically impaired in their ability to produce the cytokines 
IFNγ and IL‐2. Mechanistically, it was shown that cells utilizing aero‐
bic glycolysis increase the translation of IFNγ mRNA, likely mediated 
by preventing inhibitory GAPDH binding to IFNγ transcripts. Aerobic 
glycolysis has also been shown to be important in modulating T cell 
proliferation. Inhibiting glucose metabolism with 2‐deoxyglucose 
(2‐DG) in vivo partially inhibits T cell proliferation in an adoptive 
transfer experiment,81 and 2‐DG treatment was also shown to pro‐
tect mice from EAE.112 Perhaps unexpectedly, T cells use OXPHOS 
in addition to aerobic glycolysis to aid their activation and prolifer‐
ation. Treatment of cells with the ATP synthase inhibitor oligomycin 
impaired T cell activation and proliferation.113
In addition to Glut1 and glucose enabling mTOR signals, amino 
acid signaling also activates mTOR signaling,63,70 and several groups 
uncovered an important role for amino acid uptake in T cell function. 
T cell‐specific deletion of Slc7a5, a protein that hetero‐dimerizes 
with CD98 to form a system L transporter, has profound effects on T 
cell biology. System‐L transporters are critical for the import of leu‐
cine and other large neutral amino acids into cells. Raptor‐deficient 
T cells show impaired TCR‐induced CD98 upregulation, suggesting 
that CD98 may be an mTOR target.82 Slc7a5‐deficient T cells cannot 
proliferate, fail to differentiate into Th1 and Th17 effector subsets, 
and cannot efficiently undergo metabolic reprogramming to aerobic 
glycolysis.110 Slc7a5‐deficient T cells cannot sustain the mTOR path‐
way or sustain the expression of c‐Myc protein, despite expressing 
robust c‐Myc transcript. Interestingly, mTOR translocates to the lyso‐
some in CD8+ T cells following in vitro TCR stimulation, and mTOR‐
lysosome colocalization was stronger in cells that expressed higher 
levels of Slc7a5.114 Slc7a5 is also a key transporter of the amino acid 
methionine in T cells, and methionine import was shown to be critical 
for full T cell activation. This is because T cells use methionine both 
for the synthesis of new proteins and for generating donor methyl 
groups for methylation of histones and nucleic acids. Interestingly, 
naïve T cells express all of the key enzymes required for the metab‐
olism of methionine, suggesting they are primed to carry out these 
metabolic steps, and the ability to import methionine via Slc7a5 is 
a rate‐limiting step in this process.115 These studies imply that TCR 
signals and amino acid uptake are tightly coupled in T cells to pro‐
mote mTOR signaling, metabolism, and effector function in T cells.
19  | C‐MYC A S A CRITIC AL DECIDER
As discussed above, c‐Myc is a translational target of mTOR. c‐Myc 
itself also plays a critical role in metabolic reprogramming of T cells. 
Conditional deletion of Myc using a floxed allele crossed to a ta‐
moxifen‐inducible Cre profoundly alters T cell biology.81 Myc‐defi‐
cient cells showed impaired proliferation in vitro and in vivo and did 
not increase their cell size upon T cell activation like WT activated 
lymphocytes do. Myc deficiency has a selective effect on distinct 
metabolic programs, as glycolysis and glutamine metabolism were 
impaired in Myc‐deficient T cells, but mitochondrial oxidation of glu‐
cose (OXPHOS) and fatty acids were not affected. Functionally, Myc 
expression correlates with and controls upregulation of the trans‐
ferrin receptor CD71, revealing an intimate link between c‐Myc and 
nutrient import.116
In two provocative studies, it was demonstrated that the deci‐
sive function of c‐Myc is inherited in an asymmetric manner in CD8+ 
T cells. Specifically, in the process of cell division, the daughter cell 
more proximal to the original parental cell receives more c‐Myc pro‐
tein than the distal daughter cell.114,117 This finding was extended to 
mTOR pathway components such as P‐S6 and nutrient transport‐
ers such as CD98: these were also enriched in the c‐Mychigh, prox‐
imal daughter cells when compared to the c‐Myclow distal daughter 
cells. Intriguingly, inheritance of c‐Myc in the first cell division also 
appeared to correlate with the differentiation state of the CD8+ T 
cell. Sorted c‐Mychigh cells transferred into recipients that were sub‐
sequently immunized with Influenza A dominated the immune re‐
sponse, acting more like effector cells, while Myclow cells dominated 
the memory response.117 It is still unclear how this effector/memory 
dichotomy with respect to c‐Myc inheritance is explained, as the 
cells continue to divide during the course of an immune response. 
Nevertheless, mTOR is likely to play a role in this asymmetric cell 
division. By transiently inhibiting mTOR via rapamycin treatment, 
Borsa et al were able to increase asymmetric divisions and memory 
cell formation in ex vivo stimulated CD8+ T cells.118
To this point we have focused on the events that happen after 
antigen recognition and the role that mTOR signaling has in mediat‐
ing this response. However, to effectively mediate this response, T 
cells must be poised to do so. This has led to the hypothesis that T 
cells are primed for activity by tonic signals generated by TCR/pMHC 
interactions from seeing self‐peptides, which lower the threshold for 
T cell activation.119‐122 We will first define tonic or basal signaling 
and provide a brief overview of the literature exploring tonic sig‐
nals in lymphocytes. For a more comprehensive overview of tonic 
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signaling in T and B cells, we point the readers to a review from our 
lab and the Zikherman lab.120 Next, we will detail some of our work 
that demonstrates that the mTORC1 pathway is particularly active in 
the basal state in T cells.
20  | TONIC SIGNAL S FROM SEEING SELF
Tonic signals are characterized by low‐level recruitment and activa‐
tion of the proximal kinases and signaling molecules downstream of 
the TCR. Early studies indicated that both thymocytes and resting T 
cells in the lymph node exhibit constitutive phosphorylation of the 
TCR zeta chain and recruitment of Zap‐70.122‐128 Accordingly, tonic 
signals in T cells are generated through low affinity stimulation of 
the TCR. In vivo, one source of this low affinity interaction in T cells 
are self‐pMHC, as tonic signaling is dampened by the administration 
of MHC blocking antibodies.122 Thus, as T cells circulate in the blood 
they make few cell‐cell contacts and receive very little tonic TCR ac‐
tivity. Conversely, upon entering secondary lymphoid organs, which 
are densely packed with MHC‐expressing cells, T cells make fre‐
quent contacts and generate these sub‐threshold, tonic signals.62,122 
Intriguingly, transfer of CD4+ T cells into MHCII‐deficient recipi‐
ent mice119 yields a different result from the experiments utilizing 
MHCII blocking antibodies. T cells transferred into class II‐deficient 
mice take on an activated phenotype and were reactive against skin 
grafts, leading the authors to propose that MHCII expression in the 
periphery is important for dampening T cell activity.
Work from our lab and others suggests that tonic signaling can 
both prime T cells for activity, consistent with the Stefanova study, 
while other tonic signaling pathways can promote a quiescent state, 
consistent with the Bhandoola study. We propose that tonic signals 
carry out this dual function to maintain T cells in a primed‐yet‐quies‐
cent state: this enables T cells to be rapidly activated when they do 
encounter cognate foreign antigen, yet prevents spontaneous acti‐
vation in response to self, thereby preventing autoimmune damage.
In recent years, two reporters of tonic signaling have been identi‐
fied: the surface marker CD5, as well as the orphan nuclear hormone 
receptor Nur77 (read‐out by levels of GFP in a reporter mouse). Both 
are expressed at a level that correlates with the amount of tonic signal 
a cell receives.62,129,130 These reporters have demonstrated that there 
is a range or continuum of CD5 or Nur77‐GFP expression within the 
T cell pool, indicating heterogeneity with respect to the level of tonic 
signal T cells receive. Some cells exhibit high tonic signaling (high CD5 
or Nur77‐GFP), and others have low tonic signals (low CD5 or Nur77‐
GFP).62,129,130 Use of these reporters has demonstrated that cells 
with high tonic signaling out‐proliferate their lower tonic signaling 
counterparts in bacterial and viral infection models, indicating that 
the level of tonic signal a T cell receives impacts its function.
Despite this recent interest in tonic signaling, we still have a rel‐
atively limited understanding of what pathways are active in a tonic 
fashion in T cells as a result of TCR‐self pMHC interactions. This is in 
contrast to the signaling pathways that are engaged following TCR 
ligation by cognate antigen, which have been very well described. It 
will be interesting to define the similarities and differences between 
antigen‐induced signaling pathways and tonic signaling pathways. 
Recent work from our lab has utilized two mouse models wherein 
tonic signaling becomes dysregulated and used these models to de‐
lineate tonic signaling pathways and determine their role in T cell 
function.62,121 We will next discuss these two mouse models, one 
of which points to a mechanism for how tonic signals maintain T cell 
quiescence, and the other demonstrates that a distinct tonic signal‐
ing pathway can prime T cells for activation.
20.1 | Tonic LAT‐HDAC7 signals curb T cell activity 
by promoting transcription of negative regulators
As discussed, the linker for activation of T cells (LAT) is phos‐
phorylated at conserved tyrosine residues upon TCR ligation. 
Mutation of one of these residues, tyrosine 136, to phenylalanine 
(Y136F) leads to an intriguing phenotype: the mice have a partial 
block in the development of thymocytes into T cells; those T cells 
that do populate the periphery expand rapidly and spontaneously 
secrete the Th2 cytokine IL‐4 even without ex vivo restimula‐
tion. Furthermore, when LAT is inducibly deleted in peripheral T 
cells or the Y136F point mutation is inducibly knocked‐in to the 
endogenous LAT locus, the mice still exhibit lymphoproliferation 
and Th2‐biased differentiation, indicating that these phenotypes 
develop independently of thymocyte development.131,132 Despite 
the fact that LAT‐deficient or LAT‐pointmutated T cells aberrantly 
proliferate and produce cytokines, they are refractory to ex vivo 
stimulation via the TCR and are unable to flux calcium, produce 
critical cytokines such as IL‐2, and divide.132
This paradox described above led our group to hypothesize that 
LAT transmits a tonic signal in T cells, and loss of this tonic signal 
upon LAT perturbation drives the lymphoproliferation and Th2 
differentiation. To uncover the mechanism by which tonic signals 
through LAT could impact T cell homeostasis, we first turned to 
LAT‐deficient cell lines. We had previously demonstrated that LAT 
impacts basal transcription, as a Jurkat T cell line deficient for LAT 
(J.CaM2) exhibited impaired expression of the Rag genes as well as 
the alpha chain of the TCR (Tcra).126 This gene expression could be 
restored by treating the cells with the HDAC inhibitor trichostatin A 
(TSA), suggesting that tonic LAT‐HDAC signals impact gene expres‐
sion.133 To address this in primary T cells from mice, we performed 
microarray analysis on WT CD4+ CD44low (naïve) T cells, as well as 
cells from mice where LAT was inducibly deleted or point‐mutated 
to Y136F.121 We found a cluster of genes was significantly downreg‐
ulated in LATKO or LATY136F cells, and many of these genes had been 
previously proposed as targets of the epigenetic regulator histone 
deacetylase 7 (HDAC7).134,135
We found that tonic signals impact the basal phosphorylation 
and subcellular localization of HDAC7: freshly isolated CD4+ T 
cells have highly phosphorylated HDAC7, which is localized to the 
cytoplasm. HDAC7 is dephosphorylated and localized to the nu‐
cleus when cells are deprived of tonic signals (done experimentally 
by resting in non‐stimulatory media at low‐density). When LAT is 
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perturbed and the tonic signal through LAT is lost, HDAC7 is de‐
phosphorylated and localized to the nucleus, where it represses its 
target genes. Functionally, we found that lower expression of one 
of these targets, Nr4a1, which encodes Nur77, leads to enhanced T 
cell proliferation. Additionally, mice heterozygous for Irf4 in T cells, 
which have reduced but not absent Irf4 protein, exhibit a subtle in‐
crease in their ability to differentiate to Th2 in vitro. We hypothesize 
that the Th2‐biased lymphoproliferation observed in the LAT‐per‐
turbed mouse model is driven in part to reduced expression of these 
HDAC7 target genes Nr4a1 and Irf4. Thus, in WT cells, a tonic LAT‐
HDAC7 signal promotes low‐level expression of target genes that 
function to curb T cell proliferation and differentiation.
20.2 | Selective tonic mTOR signals in T cells
The LAT mouse model demonstrates a context where a loss‐of‐func‐
tion tonic signal leads to altered T cell functionality. In contrast, we 
also recently characterized a mouse model with a gain of function 
tonic signal, called the Rasgrp1Anaef mouse. Our work points to a 
novel tonic Rasgrp1‐mTORC1‐S6 signaling pathway that promotes T 
cell differentiation and mRNA translation.
The Rasgrp1Anaef mouse was identified in an N‐ethyl‐N‐nitro‐
sourea (ENU) chemical mutagenesis screen for exhibiting activated 
(CD44high) CD4+ T cells and anti‐nuclear antibodies (ANAs) in the 
serum. The mice developed autoantibodies when T cells harbor the 
Anaef mutation but B cells are WT, indicating that T cell help to B 
cells is altered in these animals.56 We also found that the CD4+ T 
cells in the Rasgrp1Anaef mouse exhibit an autoreactive TCR reper‐
toire, revealed using the Nur77‐GFP reporter.62 Given this, we fur‐
ther characterized these mice for features of T cell dysregulation and 
immunopathology. We found that they had expanded populations of 
follicular helper‐like (Tfh‐like, PD1high Helios+) and peripheral helper 
T cells (Tph, PD‐1high ICOShigh CXCR5low Bcl6low) in the peripheral 
lymphoid organs, and expansion of conventional Tfh cells (PD1high 
CXCR5+) in the Peyer's Patches (PPs).56,62 The increase in the acti‐
vation marker CD44, the expansion of these populations, and the 
penetrance of ANA production increased with age.
Using phospho flow cytometry and western blotting, we found 
that Rasgrp1Anaef CD4+ T cells exhibited gain‐of‐function tonic sig‐
naling to mTORC1‐S6 relative to WT T cells (Figure 6). As discussed, 
T cells constantly see self pMHC in the peripheral lymphoid organs, 
which generates tonic signals. We hypothesized that the accumula‐
tion of tonic signals over the lifespan of a T cell led to the observed 
immunopathology in the Rasgrp1Anaef mice. To test this hypothesis, 
we treated mice with a low dose of rapamycin for 1 week to dampen 
tonic signaling in vivo. We observed a reduction in CD44 expression 
on Anaef T cells down to WT levels and a contraction of the Tfh 
population in the PPs.56,62 We also crossed Rasgrp1Anaef mice to the 
mTORchino model described previously, which has reduced mTORC1 
activity. Mice with this genetic cross had reduced CD44 levels on 
CD4+ T cells and the ANAs were resolved. These studies indicate 
that elevated mTORC1 signals drive T cell autoreactivity and immu‐
nopathology in the Rasgrp1Anaef model.
As discussed, previous work analyzing tonic signaling in T cells 
focused on signals very proximal to the TCR, such as phosphory‐
lation of the TCR zeta chains, recruitment of Zap70,122‐127 and the 
adapter LAT.121,133 Given that our results from the Rasgrp1Anaef 
mouse pointed to tonic activity to mTORC1, we explored what other 
distal, downstream effector kinase pathways might be active in the 
basal state in T cells. We focused our attention on the mTORC1‐S6, 
mTORC2‐Akt, and Ras‐Erk pathways and used a barcoding phos‐
pho‐flow cytometry approach to analyze phosphorylated proteins 
in different cell subsets immediately upon fixation, where desired. 
Resting lymph node T cells ex vivo for 2 hours in non‐stimulatory 
F I G U R E  6   Tonic translation in T cells. Constant recognition 
of self‐peptide/MHC by the TCR leads to a tone of a biochemical 
signal in T cells that we term “tonic signal”. The Roose lab 
uncovered that the tonic signal through the TCR is preferentially 
transduced to the mTORC1‐S6 pathway. We also uncovered that 
resting T cells have a pattern of baseline translation in which there 
is enrichment for mTOR‐target genes. T cells from a mouse model 
with autoimmune features, Rasgrp1Anaef, have increased basal 
mTORC1‐S6 signaling and display alterations in baseline translation. 
MHC, major histocompatibility complexes; mTOR, mechanistic/
mammalian target of rapamycin; TCR, T cell receptor
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media (RPMI with amino acids and glucose but no serum) at a low cell 
density dramatically reduced P‐S6 levels compared to cells fixed im‐
mediately after isolation, with a more modest decrease in P‐AktS473, 
a readout of mTORC2 activity. P‐Erk, a readout of Ras pathway ac‐
tivity, did not decrease to a detectable degree in this 2 hour rest, 
though P‐Erk levels were quite low, nearly comparable with back‐
ground, in freshly isolated cells.62 We also analyzed P‐S6, P‐Akt, and 
P‐Erk levels in freshly isolated and fixed cells that were subsetted 
into CD4+ CD5high, which have been shown in the literature to have 
high levels of proximal tonic TCR signals, and CD4+ CD5low cells, 
which have low tonic signals. We found that CD5high cells exhibited 
higher basal P‐S6 relative to CD5low cells, indicating the mTORC1 
pathway is under tonic control. In contrast, there was no significant 
difference in P‐Akt or P‐Erk in CD5high and CD5low T cells.62 Thus, 
the mTORC1 pathway appears to be selectively active in the basal 
state in CD4+ T cells.
The Rasgrp1Anaef mice exhibited increased tonic mTORC1 signals 
in T cells, so we undertook further studies to analyze the role of 
Rasgrp1 in this process. As discussed in previous sections, Rasgrp1 
is a RasGEF that acts to facilitate the exchange of GDP for GTP on 
Ras, thereby activating Ras.26 However, despite its canonical activ‐
ity on the Ras pathway, we did not observe increases in tonic P‐
Erk, a downstream readout of Ras activity, in Rasgrp1Anaef T cells.56 
Rasgrp1 had been previously demonstrated to be important for 
TCR‐induced mTORC1 activation, as Rasgrp1‐deficient thymocytes 
did not efficiently phosphorylate S6K, S6, or 4EBP1 in response to 
TCR crosslinking with anti‐CD3. Of note, this study also demon‐
strated that Rasgrp1WT unstimulated (resting) thymocytes exhib‐
ited high basal P‐S6 compared to Rasgrp1KO cells, indicating a tonic 
Rasgrp1‐mTORC1 signal.61 To further explore the role of Rasgrp1 in 
tonic signaling, we turned to the chicken B cell line DT40, in which 
Dr. Kurosaki has made several gene deletions of lymphocyte signal‐
ing genes.136 These cells are readily amenable to genetic manipula‐
tion and transfection in vitro. We utilized a Rasgrp1/Rasgrp3 double 
deficient line (referred to as “DKO” cells here). Rasgrp1/3 DKO cells 
exhibited reduced P‐S6 compared to WT cells.62 Transient trans‐
fection of a WT Rasgrp1‐eGFP construct into DKO cells led to in‐
creased basal P‐S6 in a Rasgrp1‐dose‐dependent manner, indicating 
that Rasgrp1 is important for driving the observed tonic mTORC1 
signal. Interestingly, transient transfection of a Rasgrp1R271E‐eGFP 
construct, which encodes a variant of Rasgrp1 that lacks catalytic 
GEF activity, did not restore basal P‐S6. This suggests that the nu‐
cleotide exchange activity of Rasgrp1 is required for mTORC1 ac‐
tivity. Consistent with our data from Rasgrp1Anaef T cells, transient 
transfection of a Rasgrp1R519G‐eGFP construct, which encodes the 
Anaef variant allele, led to a subtle increase in basal P‐S6 compared 
to WT Rasgrp1.
20.3 | Tonic mTORC1 signals prime T cells for 
differentiation
As discussed, mTOR signaling is important for a number of cellular 
functions in T cells, including the differentiation from a naïve CD4+ 
T cell into a specialized sub‐type such as Th1, Th2, and Th17. We 
found that Anaef CD4+ T cells had an enhanced ability to differenti‐
ate to Th2 in vitro and secrete the canonical Th2 cytokine IL‐4.62 
This is consistent with published literature showing that Raptor‐de‐
ficient T cells, which have reduced mTORC1 signaling, are impaired 
in their ability to differentiate to Th2.82 We also found that sorted 
CD5high naive T cells (CD4+ CD44low CD5high), which have higher 
tonic mTORC1 signaling, were enhanced in their ability to differenti‐
ate to Th2 compared to CD5low cells. Mechanistically, we observed 
that Rasgrp1Anaef T cells had increased levels of the master transcrip‐
tion factor for Th2 cells, Gata3, early on during in vitro Th2 differ‐
entiation. Similarly, CD5high cells had increased Gata3 early in these 
cultures relative to CD5low cells. We hypothesize that the enhanced 
ability to differentiate to Th2 by these cells with high tonic mTORC1 
signaling may have to do with this early induction and stabilization 
of Gata3 protein.
20.4 | Baseline translation in resting T cells
As discussed above, Gata3 has been previously shown to be reg‐
ulated at the level of mRNA translation in TCR‐stimulated CD4+ 
cells. We confirmed that Gata3 is also regulated at the level of 
translation in the basal state, as freshly isolated WT CD5high T cells 
had reduced Gata3 mRNA yet elevated Gata3 protein relative to 
CD5low cells. Rasgrp1Anaef CD4+ T cells had similar levels of Gata3 
mRNA yet elevated Gata3 protein levels compared to WT T cells.62 
Gata3 is likely a translational target of mTOR, as its 5′UTR con‐
tains a PRTE, an element shown to correlate with mTOR‐depend‐
ent translation.79
In addition to Gata3, we found that naïve CD4+ T cells perform 
low‐level translation of many mRNAs, more than half of which have 
been established as mTOR translational targets in an independent 
study with mouse embryonic fibroblasts.137 We uncovered this using 
ribosome profiling, a method where ribosomes are isolated from a 
cell population of interest and the mRNAs that are actively bound 
to those ribosomes (ribosome protected fragments or RPFs) are sub‐
jected to deep sequencing.138 In parallel, the total RNA in the cell 
is sequenced, and DESeq2 can be used to identify transcripts that 
are translational targets, defined as those preferentially expressed 
in the RPF sequencing data set relative to the total mRNA in the 
cell. It would be interesting to perform ribosome profiling on WT 
mice treated with rapamycin to fully determine whether the genes 
enriched in the RPF data set are bona fide mTORC1 translational 
targets.
From our dataset, the mRNAs that were most highly translated 
in naïve T cells were enriched for genes in pathways related to mito‐
chondrion and oxidative phosphorylation, processes linked to mTOR 
signaling.62 An independent publication utilized an alternate approach 
to analyze translation, namely transcriptomic and proteomic analysis of 
T cells, and found that naive cells accumulate mRNAs for glycolysis and 
fatty acid synthesis, leading to the hypothesis that these genes con‐
tribute to the ability of T cells to rapidly undergo metabolic reprogram‐
ming upon TCR stimulation.139 We also analyzed Rasgrp1Anaef T cells 
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from young mice, which were just at the cusp of the immunopathol‐
ogy becoming penetrant, in this ribosome profiling study. There was 
a high degree of overlap in terms of translationally regulated mRNAs 
between WT and Anaef T cells (Figure 6). Glutathione metabolism was 
one functional annotation cluster identified that was unique to Anaef 
T cells.62 Whether alterations in this metabolic process are due to 
elevated tonic mTORC1 signaling, or whether they contribute to the 
immunopathology in Anaef T cells, remains an exciting open research 
question.
21  | MTOR AND AUTOIMMUNE DISE A SE
Autoimmune disease results when immune cells incorrectly rec‐
ognize self‐antigens as foreign. This leads to T cell activation and 
immune‐mediated damage of what are otherwise normal, healthy 
tissues. Many patients with autoimmune diseases are treated with 
steroids, which broadly dampen the immune system. Data from the 
LATY136F and Rasgrp1Anaef mouse models points to a role for altered 
tonic T cell signaling in immunopathology.56,62,121,131,132 A better un‐
derstanding of the signaling pathways that are active in the basal 
state, and whether dysregulation of these pathways contributes to 
disease, will be an important area of future research.
T cells from Rasgrp1Anaef mice exhibit constitutively higher activa‐
tion of the mTORC1 signaling pathway in naïve T cells. This elevated 
tonic mTORC1 signal drives the development of lupus‐like immunopa‐
thology in these animals, as pharmacological inhibition of the mTORC1 
pathway or genetically crossing in a hypomorphic mTOR allele resolves 
the disease features. As delineated in the previous section, one mech‐
anism by which mTORC1 signaling contributes to immunopathology 
may be its effects on helper T cell differentiation and translation. 
Other studies have also demonstrated a role for mTOR activity in me‐
diating autoimmune disease (Figure 7). Oaks et al demonstrated that 
rapamycin treatment of lupus‐prone mice can block the production of 
anti‐phospholipid antibodies and preserve liver function.140 In addition 
to mouse models, importantly, the role of mTOR in autoimmune dis‐
ease has also been established in human lupus patients.141
Expanding beyond mTOR, metabolic pathways are also altered in 
lupus‐like disease. In a stimulating study it was revealed that both gly‐
colysis and mitochondrial oxidative metabolism were elevated in T cells 
from a lupus‐prone mouse model. Furthermore, combined inhibition 
of these metabolic alterations with 2‐DG to dampen glycolysis and 
F I G U R E  7   mTOR and autoimmune disease. The realization that T cells from autoimmune patients as well as from genetic mouse models 
with autoimmune features have altered metabolic characteristics has stimulated the field on mTOR signaling and T cell metabolism in the 
context of autoimmune diseases. mTOR, mechanistic/mammalian target of rapamycin
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metformin to target the mitochondrion reversed lupus biomarkers in 
the mice.142 2‐DG treatment also reduced joint inflammation and other 
disease features in a moues model of rheumatoid arthritis.143 The con‐
nection between mTOR signaling and the presence of autoimmune 
features such as self‐reactive antibodies and increased inflammatory 
helper T cell subsets such as Tfh portends an exciting direction for the 
field. Given the central node metabolism plays in T cell activation, it 
will be important for future studies to understand and connect mTOR 
signaling and T cell metabolism to autoimmune disease pathology, with 
the goal of developing novel treatments (Figure 7). We point the read‐
ers to this review by Laurence Morel for a broader view of the clinical 
possibilities of metabolic inhibition.144
22  | OUTLOOK: TONIC SIGNAL S AND 
C ANCER IMMUNOTHER APY?
It is now well appreciated that the immune system is important for 
the control and elimination of cancer cells. Cancer cells utilize a num‐
ber of mechanisms to evade the detection and activity of the im‐
mune system, including the upregulation of checkpoint molecules 
that engage immune inhibitory receptors such as PD‐1 and CTLA‐4, 
and the downregulation of MHC molecules that present antigen to T 
cells.145 A number of groundbreaking cancer immunotherapies have 
been developed that aim to bolster the effector functions of T cells 
and other immune cells to kill cancer cells, or to dampen the activ‐
ity of regulatory, suppressive immune cells. We will next discuss the 
literature supporting a role for tonic signals in T cells in the context 
of cancer immunotherapy, and how a greater understanding of tonic 
signaling pathways in T cells could be leveraged to design novel and 
effective therapies (Figure 8). We will discuss both Chimeric Antigen 
Receptor (CAR) T cell therapies as well as immune checkpoint block‐
ade (ICB) therapies.
An area of intense recent research has been in the develop‐
ment and improvement of CAR T cells. To date, the FDA has ap‐
proved two CAR‐T therapies targeting CD19‐expressing B cell 
malignancies. To generate CAR T cells, T cells are isolated from 
a patient, an engineered receptor is inserted, and that genetically 
modified cell is re‐infused into the patient. The engineered re‐
ceptor is composed of several domains: an extracellular portion 
that recognizes a tumor associated antigen (such as CD19 for the 
FDA‐approved CARs), a hinge region, a transmembrane domain, 
and intracellular, ITAM‐containing signaling domains such as the 
TCR‐CD3 zeta chain and/or the 4‐1BB domain, among others.146 
The exact consequences on signaling in T cells expressing a CAR is 
an area of active research with many unknowns particularly in the 
application for solid tumors.147 As Long et al showed, some CAR 
constructs exhibited baseline phosphorylation of the CD3‐zeta 
chain due to CAR mediated, antigen independent tonic signals.148 
Further, they show that these tonic signals correlated with over‐
activation and early exhaustion, thus decreasing the anti‐tumor 
efficacy in vivo. The authors were able to rescue this effect by 
including an inhibitory 4‐1BB domain in the CAR. Intriguingly, 
when they compared the inhibitory CAR to their previous model 
they found increased transcription of metabolic genes. A separate 
study illustrated that CARs containing 4‐1BB domains persisted 
F I G U R E  8   Checkpoint blockade and 
CAR‐T cells and tonic signals. Checkpoint 
blockade in the form of anti‐CTLA4 
or anti‐PD1 as well as generation or 
CAR‐T cells to fight tumors may lead 
to increased tonic mTORC1 signaling in 
T cells. Questions such as the impact 
of T cell therapy approaches on mTOR 
signaling in T cells will be important to 
address. CAR, Chimeric Antigen Receptor; 
mTOR, mechanistic/mammalian target of 
rapamycin
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better in vivo.149 In addition, they showed enhanced glycolytic me‐
tabolism in the poorly persistent cells, and that 4‐1BB inclusion 
in the CAR drives mitochondrial biogenesis and increased oxida‐
tive phosphorylation. These studies primarily assess cellular me‐
tabolism at the functional level, but, as we have discussed in this 
review, mTOR signaling is a crucial regulator of these processes. 
Therefore, future studies will be important to understand whether 
and how the CAR may tonically engage mTOR, and how modu‐
lating mTOR signaling or metabolic pathways in CAR T cells may 
enhance their in vivo efficacy.
Beyond engineering cells and receptors, as is the case with 
CAR‐T cells, ICB has proved to be one of the most important de‐
velopments in cancer treatments to date. T cells express several 
checkpoint molecules on their surface, including CTLA‐4 and 
PD‐1, which are important for transducing inhibitory signals as 
a counterbalance to activating signals. Several of these immune 
checkpoints are upregulated on exhausted or anergic T cells.150,151 
Some work has begun to show that these molecules may also sig‐
nal in a tonic tonic fashion, which may regulate T cell function. 
For instance, Previte and colleagues investigated the role of the 
inhibitory lymphocyte activation gene‐3 (LAG‐3) in controling 
naïve T cell metabolism.152 In their work, the authors found that 
genetic deletion of LAG‐3 induced T cells to be more metabolically 
active and more proliferative under homeostatic conditions in an 
adoptive transfer model. These tonic signals to LAG‐3 were found 
to inhibit STAT5 and Akt activation, and enhancement of these 
pathways upon LAG‐3 genetic ablation lead to increased aero‐
bic glycolysis, Glut1 expression, and c‐Myc induction. Thus, this 
study provides another interesting link between tonic signals, here 
through an immune checkpoint molecule as opposed to through 
the TCR, and T cell metabolism.
Similar studies have been conducted with PD‐1. Using a lymph‐
openia‐induced proliferation model, Ellestad et al demonstrated T 
cells lacking PD‐1 repopulated Rag−/− recipient mice better than co‐
injected WT cells.153 This proliferative break was shown to be de‐
pendent upon tonic pMHC interactions as both PD‐1 deficient and 
WT T cells both fail to proliferate in Rag−/− recipients that also lack 
MHC. The authors also observed increased CD44 expression in the 
PD‐1 deficient T cells, indicating a more activated T cell phenotype. 
Whether the increased CD44 on PD‐1‐deficient T cells is driven my 
increased tonic mTORC1 signals, as in the Rasgrp1Anaef T cells, re‐
mains unknown.
Lastly, studies have also implicated the possibility for CTLA‐4 
negative co‐stimulation in the regulation of tonic signals. Knockout 
of CTLA‐4 in mice leads to aberrant T cell differentiation, indicated 
by the presence of non‐canonical CD4+ T helper cell subtypes only 
in the knockout mice.154 Intriguingly, data from this study illustrate 
the possibility that CTLA‐4 restricts tonic signaling by raising the 
threshold for differentiation of promiscuous clones. T cells from 
CTLA‐4 deficient mice may be more responsive to self‐antigens as 
well, as CTLA‐4 deletion was correlated with decreased N region in‐
sertions, which can contribute to self‐reactivity.154,155 How exactly 
CTLA‐4 may receive or transduce tonic signals remains to be defined, 
but these recent data provide an important starting point. Whether 
checkpoint inhibitors could be enhanced by co‐administration of 
small molecule inhibitors or agonists that target tonic signaling effec‐
tor molecules remains an exciting open research question. It is also 
still unknown whether tonic signals are altered in the highly suppres‐
sive tumor microenvironment and across different tumor histotypes. 
Gaining a better understanding of tonic signaling pathways in T cells, 
both downstream of the TCR and from other surface receptors such 
as immune checkpoints or nutrient transporters, as well as determin‐
ing how these tonic signaling pathways alter T cell metabolism and 
function, could enable us to optimize treatments to broaden their 
efficacy (Figure 8).
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